Authors
Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jin Seok Kim, Seong Kyu Park, Hyo Jung Kim, Jeeyun Lee, Baek-Yeol Ryoo, Young Hyeh Ko, Jooryung Huh, Woo Ick Yang, Hee Kyung Kim, Soo Kee Min, Seung-Sook Lee, In-Gu Do, Cheolwon Suh, Won Seog Kim, Consortium for Improving Survival of Lymphoma (CISL) investigators
Publication date
2012/11/1
Journal
European journal of cancer
Volume
48
Issue
17
Pages
3223-3231
Publisher
Pergamon
Description
BACKGROUND
We performed a phase II study to evaluate the efficacy of bortezomib in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas (PTCLs) based on our phase I study results.
METHODS
Patients received bortezomib on days 1 and 8 at a dose of 1.6mg/m2 in addition to CHOP every 3weeks for a total of six cycles.
RESULTS
Forty-six patients were enrolled: PTCL, not otherwise specified (PTCL-NOS, n=16), extranodal NK/T-cell lymphoma, nasal type (ENKTL, n=10), angioimmunoblastic T-cell lymphoma (AITL, n=8), ALK-negative anaplastic large-cell lymphoma (ALCL, n=6), cutaneous T-cell lymphoma (CTCL, n=5) and hepatosplenic T-cell lymphoma (n=1). Thirty patients achieved complete response (CR, 65%) and the overall response rate was 76% (35/46). Although the CR rate of ENKTL …
Total citations
Scholar articles
SJ Kim, DH Yoon, HJ Kang, JS Kim, SK Park, HJ Kim… - European journal of cancer, 2012